Exceptional Response to Everolimus in a Patient with Metastatic Castrate-Resistant Prostate Cancer Harboring a PTEN Inactivating Mutation

Exceptional Response to Everolimus in a Patient with Metastatic Castrate-Resistant Prostate Cancer Harboring a PTEN Inactivating Mutation

Prostate cancer is among the most common types of cancer in men. Early detection and proper medical intervention is crucial to ensuring successful treatment. Here we describe a patient clinically presenting with castrate-resistant prostate carcinoma. Comprehensive genomic profiling identified a PTEN...

Full description

Bibliographic Details
Main Authors: Jamie A. Kmak, Nikita Agarwal, Yuting He, Andreas M. Heilmann, Vincent A. Miller, Jeffrey S. Ross, Sumanta Kumar Pal, Siraj M. Ali, Deepak Kilari
Format: Article
Language:English
Published: Karger Publishers 2020-04-01
Series:Case Reports in Oncology
Subjects:
pten
prostate cancer
everolimus
castration resistant
mtor
Online Access:https://www.karger.com/Article/FullText/506625

Internet

https://www.karger.com/Article/FullText/506625

Similar Items